Forte Biosciences (FBRX) Operating Income (2016 - 2026)

Forte Biosciences (FBRX) has reported Operating Income for 11 consecutive years, with -$22.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Income fell 39.17% year-over-year to -$22.4 million; the TTM figure through Mar 2026 stood at -$77.0 million (down 71.35% YoY), while the FY2025 annual figure was -$70.7 million, down 93.04% from the prior year.
• Operating Income improved to -$22.4 million in Q1 2026 per FBRX's latest filing, from -$24.6 million in the prior quarter.
• Across five years, Operating Income topped out at -$2.5 million in Q1 2022 and bottomed at -$24.6 million in Q4 2025.
• Historically, Operating Income has averaged -$10.4 million across 5 years, with a median of -$8.6 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Income jumped 55.54% — and 2025, when it tumbled 234.25%.
• Forte Biosciences' Operating Income stood at -$4.9 million in 2022, then dropped by 29.2% to -$6.4 million in 2023, then slipped by 15.2% to -$7.4 million in 2024, then sank by 234.25% to -$24.6 million in 2025, then advanced by 8.68% to -$22.4 million in 2026.
• Business Quant data shows FBRX's Operating Income at -$22.4 million in Q1 2026, -$24.6 million in Q4 2025, and -$18.4 million in Q3 2025.